- Home
- SRFM vs ASMB Comparison
SRFM vs ASMB Comparison
Compare SRFM & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- ASMB
- Stock Information
- Founded
- SRFM 2011
- ASMB 2005
- Country
- SRFM United States
- ASMB United States
- Employees
- SRFM N/A
- ASMB N/A
- Industry
- SRFM Transportation Services
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- ASMB Health Care
- Exchange
- SRFM Nasdaq
- ASMB Nasdaq
- Market Cap
- SRFM 191.9M
- ASMB 225.9M
- IPO Year
- SRFM 2023
- ASMB 2010
- Fundamental
- Price
- SRFM $3.96
- ASMB $30.99
- Analyst Decision
- SRFM Buy
- ASMB Strong Buy
- Analyst Count
- SRFM 4
- ASMB 5
- Target Price
- SRFM $5.75
- ASMB $44.25
- AVG Volume (30 Days)
- SRFM 3.5M
- ASMB 141.8K
- Earning Date
- SRFM 11-13-2025
- ASMB 11-07-2025
- Dividend Yield
- SRFM N/A
- ASMB N/A
- EPS Growth
- SRFM N/A
- ASMB N/A
- EPS
- SRFM N/A
- ASMB N/A
- Revenue
- SRFM $107,372,000.00
- ASMB $33,247,000.00
- Revenue This Year
- SRFM N/A
- ASMB $14.29
- Revenue Next Year
- SRFM $18.06
- ASMB N/A
- P/E Ratio
- SRFM N/A
- ASMB N/A
- Revenue Growth
- SRFM N/A
- ASMB 54.77
- 52 Week Low
- SRFM $1.50
- ASMB $7.75
- 52 Week High
- SRFM $9.91
- ASMB $32.44
- Technical
- Relative Strength Index (RSI)
- SRFM 38.83
- ASMB 66.83
- Support Level
- SRFM $4.07
- ASMB $27.07
- Resistance Level
- SRFM $4.50
- ASMB $31.03
- Average True Range (ATR)
- SRFM 0.45
- ASMB 1.68
- MACD
- SRFM -0.13
- ASMB 0.19
- Stochastic Oscillator
- SRFM 0.45
- ASMB 78.42
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.